These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 29177081)

  • 21. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
    Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two-year efficacy of tocilizumab in patients with active rheumatoid arthritis in clinical practice.
    Notario Ferreira I; Ferrer González MA; Morales Garrido P; González Utrilla A; García Sanchez A; Soto Pino MJ; Suero Rosario E; Caro Hernández C; Añón Oñate I; Pérez Albaladejo L; Cáliz Cáliz R
    Reumatol Clin; 2017; 13(2):78-84. PubMed ID: 27174398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.
    Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Boumpas D; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Rainer F; Pavelka K; Chartier M; Poncet C; Rauch C; Bars ML
    BMC Musculoskelet Disord; 2014 Jan; 15():14. PubMed ID: 24410774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
    Kristensen LE; Kapetanovic MC; Gülfe A; Söderlin M; Saxne T; Geborek P
    Rheumatology (Oxford); 2008 Apr; 47(4):495-9. PubMed ID: 18316338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder.
    Balogh E; Madruga Dias J; Orr C; Mullan R; Harty L; FitzGerald O; Gallagher P; Molloy M; O'Flynn E; Kelly A; Minnock P; O'Neill M; Moore L; Murray M; Fearon U; Veale DJ
    Arthritis Res Ther; 2013 Dec; 15(6):R221. PubMed ID: 24365061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry.
    Salmon JH; Gottenberg JE; Ravaud P; Cantagrel A; Combe B; Flipo RM; Schaeverbeke T; Houvenagel E; Gaudin P; Loeuille D; Rist S; Dougados M; Sibilia J; Le Loët X; Meyer O; Solau-Gervais E; Marcelli C; Bardin T; Pane I; Baron G; Perrodeau E; Mariette X;
    Ann Rheum Dis; 2016 Jun; 75(6):1108-13. PubMed ID: 26048170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries.
    Alten R; Feist E; Lorenz HM; Nüßlein H; Voll RE; Chartier M; Elbez Y; Rauch C
    Clin Rheumatol; 2019 Nov; 38(11):3049-3059. PubMed ID: 31300979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial.
    Li R; Zhao JX; Su Y; He J; Chen LN; Gu F; Zhao C; Deng XR; Zhou W; Hao YJ; Xue Y; Liu HX; Zhao Y; Zou QH; Liu XY; Zhu P; Sun LY; Zhang ZL; Zou HJ; Li XF; Liu Y; Fang YF; Keystone E; McInnes IB; Li ZG
    Medicine (Baltimore); 2016 Jul; 95(28):e3968. PubMed ID: 27428186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
    Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
    Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry.
    Harrold LR; Litman HJ; Connolly SE; Alemao E; Kelly S; Rebello S; Hua W; Kremer JM
    Rheumatol Ther; 2019 Jun; 6(2):217-230. PubMed ID: 30868550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The good EULAR response at the first year is strongly predictive of clinical remission in rheumatoid arthritis: results from the TARAC cohort.
    Darawankul B; Chaiamnuay S; Pakchotanon R; Asavatanabodee P; Narongroeknawin P
    Clin Rheumatol; 2015 Jan; 34(1):43-9. PubMed ID: 25060487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment.
    Miwa Y; Saito M; Furuya H; Yanai R; Ikari Y; Hayashi T; Kasama T; Toyoshima Y; Inagaki K
    Intern Med; 2017 Sep; 56(17):2271-2275. PubMed ID: 28794381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
    Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
    J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis.
    Alemao E; Postema R; Elbez Y; Mamane C; Finckh A
    Clin Exp Rheumatol; 2020; 38(3):455-466. PubMed ID: 31770089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.
    Rubbert-Roth A; Enejosa J; Pangan AL; Haraoui B; Rischmueller M; Khan N; Zhang Y; Martin N; Xavier RM
    N Engl J Med; 2020 Oct; 383(16):1511-1521. PubMed ID: 33053283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.
    Wechalekar MD; Lester S; Proudman SM; Cleland LG; Whittle SL; Rischmueller M; Hill CL
    Arthritis Rheum; 2012 May; 64(5):1316-22. PubMed ID: 22135142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis.
    Sandberg ME; Bengtsson C; Källberg H; Wesley A; Klareskog L; Alfredsson L; Saevarsdottir S
    Ann Rheum Dis; 2014 Nov; 73(11):2029-33. PubMed ID: 24818635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs.
    Narvaez J; Díaz-Torné C; Ruiz JM; Hernandez MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
    Clin Exp Rheumatol; 2011; 29(6):991-7. PubMed ID: 22133052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.